Navigation Links
Misonix Announces New Distribution Agreement For Denmark
Date:4/2/2013

eir history of successfully introducing cutting edge products to the Danish market is well known to us," said Michael A. McManus, Jr. , President and Chief Executive Officer of Misonix. 

About Misonix
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activitie
'/>"/>

SOURCE Misonix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Misonix Announces New Distribution Agreement For Panama
2. Misonix And SIAD Healthcare Renew Distribution Agreement For Italy
3. Misonix Exhibits at Major Worldwide Spine Conference
4. Misonix Adds Industry Veteran To Management Team
5. Misonix Participates In Cleveland Spine Review
6. Misonix And Soelim Create New Distribution Alliance For South Korea
7. Misonix Inks New Distribution Agreement For Croatia And Slovenia
8. Misonix Attends International Meeting On Advanced Spine Techniques (IMAST) - Introduces New Product
9. Misonix Adds 6 Spine Sales Agencies In The U.S.
10. Misonix Product Featured At Neurosurgery Congress
11. Misonix Reports Strong Revenue Increases for the Three Months and Full-Year Ended June 30, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Texas , Jan. 15, 2014  Humberto C. Antunes,  ... Achievement Award" from the Journal of Drugs in ... & Clinical Conference (ODAC). The event is January 17-20, 2014, at ... Florida . The ODAC is ...
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... May 19, 2007 /PRNewswire/ -- Data presented,today at ... mg tablets administered once-daily for five days is ... for 10,days for the treatment of complicated urinary ... Inc., the company that markets LEVAQUIN in the,U.S., ...
... 19, 2007 - King,Pharmaceuticals, Inc. (NYSE:KG) reported ... trial evaluating Altace (ramipril) 20mg and the,combination ... were,presented this weekend at the American Society ... and Exposition,(ASH 2007) in Chicago, Illinois. The ...
Cached Medicine Technology:Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 2Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 3Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 4King Pharmaceuticals Reports Efficacy of Altace 20mg And Efficacy,of a Combination of Altace 20mg And Hydrochlorothiazide 25mg For,24-hour Blood Pressure Control 2King Pharmaceuticals Reports Efficacy of Altace 20mg And Efficacy,of a Combination of Altace 20mg And Hydrochlorothiazide 25mg For,24-hour Blood Pressure Control 3King Pharmaceuticals Reports Efficacy of Altace 20mg And Efficacy,of a Combination of Altace 20mg And Hydrochlorothiazide 25mg For,24-hour Blood Pressure Control 4King Pharmaceuticals Reports Efficacy of Altace 20mg And Efficacy,of a Combination of Altace 20mg And Hydrochlorothiazide 25mg For,24-hour Blood Pressure Control 5
(Date:4/18/2014)... Johns Hopkins University School of Medicine researchers have been ... for diabetes, Novo Nordisk announced this month. Of the ... and Obesity Biologics Science Forum Program, only four projects ... Hopkins researchers. They are Jonathan Powell, M.D., Ph.D.; G. ... , Jonathan Powell, a professor of oncology, will use ...
(Date:4/18/2014)... French . ... medicine. A team led by Ludwik Leibler from the ... Didier Letourneur from the Laboratoire Recherche Vasculaire Translationnelle (INSERM/Universits ... the principle of adhesion by aqueous solutions of nanoparticles ... and tissues. This easy-to-use gluing method has been tested ...
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... Pen ... Technology, ... system, a new innovative solution for,digitally capturing patient information that is ... administer. The Docuscan Patient History solution with Paros(TM) technology enables,digital ...
... pop stars are more than twice as likely as the ... within a few years of becoming famous, reveals research published ... Health. , The findings are based on more than 1050 ... fame between 1956 and 1999. , All the musicians featured ...
... Steps for Young Children Program, which added behavior ... benefit families more than two years after the ... from the Johns Hopkins Bloomberg School of Public ... Steps included greater satisfaction among parents with their ...
... give rise to exuberant scarring, which can lead to ... disfigurement. In a review article in this weeks PLoS ... of Medicine) and colleagues examine the process of such ... the research areas that are likely to lead to ...
... ARLINGTON, Va., Aug. 22 The American,Psychiatric Association (APA) ... review of scientific evidence that led to the,approval of ... The APA is pleased that the approvals are a ... which was designed to,encourage research that leads to this ...
... safety of blood supply by detecting virus ... earlier in infection cycle., ... & Drug Administration (FDA) today approved its biologics,license application for the ... blood and plasma. West Nile virus, which can,cause serious health issues, ...
Cached Medicine News:Health News:New 'Smart' Technology Makes Patient Data Collection Easier, More Efficient 2Health News:Pop stars more than twice as likely to die an early death 2Health News:Practice-based intervention has sustained benefits for children and families 2Health News:APA Comments on FDA's First Approval of Medication to Treat Pediatric Schizophrenia and Bipolar Disorder 2Health News:FDA Approves New Roche West Nile Virus Blood Screening Test 2Health News:FDA Approves New Roche West Nile Virus Blood Screening Test 3
... American Proficiency Institute offers innovative proficiency ... technical support. As a result, API is ... in the world with over 12,000 laboratories ... advantages of using API:, Paperless ...
... APC-R FVL is a new functional test ... for Activated Protein C Resistance caused by ... contrast to other commercially available methods, Pefakit ... C or S, Lupus Anticoagulants, Elevated FVIII ...
... is an advanced ophthalmic laser platform, ... technologies, improved operability, fast operation, super ... with versatility for combination laser systems. ... and adds several unique features such ...
The Properdin ELISA Kit is approved for in-vitro diagnostic use and measurement of properdin serum levels, relevant in cases of recurrent meningococcal infection and recurrent bacterial meningitis....
Medicine Products: